Journal Article Summary
The article discusses a case involving a patient with non-alcoholic steatohepatitis (NASH) and cirrhosis who experienced liver decompensation after rapid weight loss due to semaglutide treatment. This topic is significant because semaglutide, a medication used for weight management and diabetes, is increasingly prescribed, yet there is limited safety data for patients with liver conditions like NASH cirrhosis. Understanding the potential risks associated with this medication in vulnerable populations is crucial for ensuring patient safety.
The study reports on a 68-year-old woman with compensated NASH cirrhosis who was prescribed semaglutide to help manage her diabetes and obesity. After losing 10 kg in just eight weeks, she developed serious complications, including hepatic encephalopathy and ascites, which led to an increase in her Model for End-stage Liver Disease-Na (MELD-Na) score. Following the cessation of semaglutide and aggressive nutritional support, she gradually regained her weight, and her liver function improved, allowing her to be removed from the transplant waitlist.
However, the article highlights several limitations, including the fact that this is a single case report, which may not represent broader patient experiences. It emphasizes the importance of monitoring patients closely when using semaglutide, especially those with liver conditions, and suggests that healthcare providers should be cautious in prescribing this medication. Patients are encouraged to discuss any concerns about weight loss or liver health with their healthcare professionals, particularly if they notice rapid weight loss or symptoms of liver decompensation.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Peverelle Matthew, Ng Jonathan, Peverelle James, Hirsch Ryan D., Testro Adam. Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis. World Journal of Gastroenterology 2023. DOI: 10.3748/wjg.v29.i47.6165. PMID: 38186682. PMCID: PMC10768411.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
